BR112023022580A2 - Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças - Google Patents
Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doençasInfo
- Publication number
- BR112023022580A2 BR112023022580A2 BR112023022580A BR112023022580A BR112023022580A2 BR 112023022580 A2 BR112023022580 A2 BR 112023022580A2 BR 112023022580 A BR112023022580 A BR 112023022580A BR 112023022580 A BR112023022580 A BR 112023022580A BR 112023022580 A2 BR112023022580 A2 BR 112023022580A2
- Authority
- BR
- Brazil
- Prior art keywords
- pi3k
- chromenone
- phosphoinositide
- kinase
- diseases
- Prior art date
Links
- 108091007960 PI3Ks Proteins 0.000 title abstract 6
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title abstract 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title abstract 6
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000003281 allosteric effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças. a presente invenção refere-se a compostos de fórmula (i) como inibidores alostéricos de cromenona de fosfoinositídeo 3 quinase (pi3k) úteis no tratamento de doenças ou distúrbios associados à modulação de pi3k, fórmula (i): ou sais farmaceuticamente aceitáveis dos mesmos em que r, r1, r2, r3, r4, r5, r6, r7, e r8, são conforme descrito no presente documento. a invenção ainda se refere a métodos para fabricar e usar compostos da fórmula (i) ou sais farmaceuticamente aceitáveis dos mesmos.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183366P | 2021-05-03 | 2021-05-03 | |
| US202163227652P | 2021-07-30 | 2021-07-30 | |
| US202163250564P | 2021-09-30 | 2021-09-30 | |
| US202163253412P | 2021-10-07 | 2021-10-07 | |
| US202163253282P | 2021-10-07 | 2021-10-07 | |
| PCT/US2022/027306 WO2022235575A1 (en) | 2021-05-03 | 2022-05-02 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022580A2 true BR112023022580A2 (pt) | 2024-01-09 |
Family
ID=81748709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022580A BR112023022580A2 (pt) | 2021-05-03 | 2022-05-02 | Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230014445A1 (pt) |
| EP (1) | EP4334312A1 (pt) |
| JP (1) | JP2024516993A (pt) |
| KR (1) | KR20240004744A (pt) |
| AU (1) | AU2022269566A1 (pt) |
| BR (1) | BR112023022580A2 (pt) |
| CA (1) | CA3216800A1 (pt) |
| IL (1) | IL308191A (pt) |
| TW (1) | TW202309011A (pt) |
| WO (1) | WO2022235575A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20230517A (es) | 2021-05-03 | 2023-11-28 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| TWI829179B (zh) | 2021-05-27 | 2024-01-11 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 |
| TW202329930A (zh) * | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| TW202334137A (zh) * | 2021-11-03 | 2023-09-01 | 美商薩諾管理公司 | Ｐｉ３ｋ抑制劑及治療癌症之方法 |
| WO2023104111A1 (en) * | 2021-12-08 | 2023-06-15 | Nanjing Zenshine Pharmaceuticals Co., Ltd. | Fused heterocyclic compounds as pi3kalpha inhibitors |
| WO2023207881A1 (en) * | 2022-04-24 | 2023-11-02 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| TW202408481A (zh) * | 2022-04-29 | 2024-03-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 |
| WO2024097721A1 (en) | 2022-11-02 | 2024-05-10 | Petra Pharma Corporation | Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4646626B2 (ja) * | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド３−キナーゼβの阻害 |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
-
2022
- 2022-05-02 WO PCT/US2022/027306 patent/WO2022235575A1/en active Application Filing
- 2022-05-02 US US17/734,745 patent/US20230014445A1/en active Pending
- 2022-05-02 TW TW111116591A patent/TW202309011A/zh unknown
- 2022-05-02 AU AU2022269566A patent/AU2022269566A1/en active Pending
- 2022-05-02 BR BR112023022580A patent/BR112023022580A2/pt unknown
- 2022-05-02 EP EP22724368.0A patent/EP4334312A1/en active Pending
- 2022-05-02 KR KR1020237041193A patent/KR20240004744A/ko active Search and Examination
- 2022-05-02 JP JP2023567887A patent/JP2024516993A/ja active Pending
- 2022-05-02 CA CA3216800A patent/CA3216800A1/en active Pending
- 2022-05-02 IL IL308191A patent/IL308191A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024516993A (ja) | 2024-04-18 |
| AU2022269566A1 (en) | 2023-11-02 |
| IL308191A (en) | 2024-01-01 |
| TW202309011A (zh) | 2023-03-01 |
| CA3216800A1 (en) | 2022-11-10 |
| WO2022235575A1 (en) | 2022-11-10 |
| KR20240004744A (ko) | 2024-01-11 |
| EP4334312A1 (en) | 2024-03-13 |
| US20230014445A1 (en) | 2023-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023022580A2 (pt) | Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças | |
| BR112023022940A2 (pt) | Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças | |
| BR112022019918A2 (pt) | Inibidores de cromenona alostérica de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças associadas à modulação de pi3k | |
| BR112023022890A2 (pt) | Inibidores de cromenona alostéricos de fosfoinositídio 3-cinase (pi3k), composições farmacêuticas que os compreendem e usos dos mesmos | |
| UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| BR112023016299A2 (pt) | Composições e métodos para inibir kras | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BRPI0912294B8 (pt) | compostos de triazina que inibem p13 quinase e mtor, e composições farmacêuticas dos mesmos | |
| CO2021015318A2 (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| BR112021017831A2 (pt) | Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose | |
| BRPI0914404A2 (pt) | "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente" | |
| CO2022017072A2 (es) | Imidazopiridazinas como moduladores de il-17 | |
| BR112022024597A2 (pt) | Compostos de 4-oxo-3,4-di-hidroquinazolinona para o tratamento de doenças e distúrbios associados com braf | |
| CR20190361A (es) | Dendrímeros terapéuticos | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| BR112022006572A2 (pt) | Inibidores orais do fator d do complemento | |
| BR112022010181A2 (pt) | Composto tri-heterocíclico como inibidor de jak e uso do mesmo | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| BR112023023425A2 (pt) | Compostos heterocíclicos substituídos | |
| BR112021018335A2 (pt) | Derivados de benzodiazepina como inibidores de rsv | |
| CO2024003723A2 (es) | Compuestos de imidazopiridazina inhibidores de il-17 | |
| BR112023017626A2 (pt) | Derivados de diazepina úteis no tratamento de clostridium dificile | |
| BR112023016970A2 (pt) | Compostos heterocíclicos antivirais |